Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

COX-2, NSAID Concomitant Use With GI Protective Drugs Is Similar, Study Says

Executive Summary

COX-2 inhibitor patients use gastro-protective drugs at approximately the same rate as patients taking traditional nonsteroidal anti-inflammatory drugs, an Express Scripts-sponsored study suggests

You may also be interested in...



Novartis Prexige Is “Not Approvable;” COX-2 Launch At Least Two Years Away

The liver safety profile of Novartis' Prexige appears to be one factor behind FDA's request for additional studies on the COX-2 inhibitor prior to approval in osteoarthritis and acute pain

California Health Plans Promoting Generics Versus Brand Statins, COX-2s

Four California health plans are mailing $10 coupons to physicians to cover the copay for a new prescription for one of 12 drugs available under the Generic Advantage program

COX-2 Inhibitors Overused As Short-Term Therapy, Express Scripts Says

COX-2 inhibitors are over-prescribed for short-term pain and therefore do not achieve the gastrointestinal safety benefit needed to be considered cost-effective, Express Scripts' drug utilization studies conclude

Related Content

UsernamePublicRestriction

Register

PS043079

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel